title: Initial experience with lung donation after cardiocirculatory death in Canada.
abstract: BACKGROUND
  Organ donation after cardiac death (DCD) has the potential to alleviate some of the shortage of suitable lungs for transplantation. Only limited data describe outcomes after DCD lung transplantation. This study describes the early and intermediate outcomes after DCD lung transplantation in Canada.
  
  
  METHODS
  Data were collected from donors and recipients involved in DCD lung transplantations between June 2006 and December 2008. Described are the lung DCD protocol, donor characteristics, and the occurrence of post-transplant events including primary graft dysfunction (PGD), bronchial complications, acute rejection (AR), bronchiolitis obliterans syndrome (BOS), and survival.
  
  
  RESULTS
  Successful multiorgan controlled DCD increased from 4 donors in 2006 to 26 in 2008. Utilization rates of lungs among DCD donors were 0% in 2006, 11% in 2007, and 27% in 2008. The lung transplant team evaluated 13 DCD donors on site, and lungs from 9 donors were ultimately used for 10 recipients. The 30-day mortality was 0%. Severe PGD requiring extracorporeal membrane oxygenation occurred in 1 patient. Median intensive care unit stay was 3.5 days (range, 2-21 days). Hospital stay was 25 days (range, 9-47 days). AR occurred in 2 patients. No early BOS has developed. Nine (90%) patients are alive at a median of 270 days (range, 47-798 days) with good performance status and lung function. One patient died of sepsis 17 months after transplantation.
  
  
  CONCLUSIONS
  DCD has steadily increased in Canada since 2006. The use of controlled DCD lungs for transplantation is associated with very acceptable early and intermediate clinical outcomes.
authors.affiliation: The Toronto Lung Transplant Program, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Marcelo
authors.initials: M
authors.lastname: Cypel
authors.forename: Masaaki
authors.initials: M
authors.lastname: Sato
authors.forename: Erkan
authors.initials: E
authors.lastname: Yildirim
authors.forename: Wojtek
authors.initials: W
authors.lastname: Karolak
authors.forename: Fengshi
authors.initials: F
authors.lastname: Chen
authors.forename: Jonathan
authors.initials: J
authors.lastname: Yeung
authors.forename: Carlos
authors.initials: C
authors.lastname: Boasquevisque
authors.forename: Victoria
authors.initials: V
authors.lastname: Leist
authors.forename: Lianne G
authors.initials: LG
authors.lastname: Singer
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yasufuku
authors.forename: Marc
authors.initials: M
authors.lastname: Deperrot
authors.forename: Thomas K
authors.initials: TK
authors.lastname: Waddell
authors.forename: Shaf
authors.initials: S
authors.lastname: Keshavjee
authors.forename: Andrew
authors.initials: A
authors.lastname: Pierre
mesh_terms: D000293:Adolescent; D000328:Adult; D002170:Canada; D003643:Death; D005260:Female; D006323:Heart Arrest; D006801:Humans; D016040:Lung Transplantation; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D014019:Tissue Donors; D020858:Tissue and Organ Harvesting; D009927:Tissue and Organ Procurement; D016896:Treatment Outcome